Morfinmetabolisme-farmakokinetik og-dynamik

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Morfinmetabolisme-farmakokinetik og-dynamik. / Andersen, G; Christrup, Lona Louring; Sjøgren, P.

In: Ugeskrift for Laeger, Vol. 159, No. 22, 26.05.1997, p. 3383-6.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Andersen, G, Christrup, LL & Sjøgren, P 1997, 'Morfinmetabolisme-farmakokinetik og-dynamik', Ugeskrift for Laeger, vol. 159, no. 22, pp. 3383-6.

APA

Andersen, G., Christrup, L. L., & Sjøgren, P. (1997). Morfinmetabolisme-farmakokinetik og-dynamik. Ugeskrift for Laeger, 159(22), 3383-6.

Vancouver

Andersen G, Christrup LL, Sjøgren P. Morfinmetabolisme-farmakokinetik og-dynamik. Ugeskrift for Laeger. 1997 May 26;159(22):3383-6.

Author

Andersen, G ; Christrup, Lona Louring ; Sjøgren, P. / Morfinmetabolisme-farmakokinetik og-dynamik. In: Ugeskrift for Laeger. 1997 ; Vol. 159, No. 22. pp. 3383-6.

Bibtex

@article{8dc75195a3684dcdbbc81dcdf71fe278,
title = "Morfinmetabolisme-farmakokinetik og-dynamik",
abstract = "With the increasing use of morphine, growing interest for the clinical implications of its metabolites, morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G) has emerged in the literature. M-6-G binds to the opioid receptor and has analgesic properties in man. Clinical studies have not delivered strong evidence of significant correlation between the concentration of morphine and its glucuronides in plasma and cerebrospinal fluid and pharmacodynamics such as analgesia. There is no clinical evidence to indicate that M-6-G has a pronounced respiratory depressing effect in man, while the literature contains conflicting reports with regard to other side-effects. M-3-G does not bind to the m-opioid receptor and consequently has no antinociceptive effects. Studies in rodents have shown that morphine, M-6-G and especially M-3-G may induce hyperalgesia, allodynia and myoclonus. It is assumed that these side effects are caused by a spinal antiglycinergic mechanism. The role of M-3-G in morphine antagonism and development of tolerance has not yet been settled. As M-3-G and M-6-G are eliminated by the kidneys, renal insufficiency will lead to accumulation of these. Accordingly dosage should be reduced or other opioids be considered in such cases.",
keywords = "Humans, Morphine, Receptors, Opioid, mu",
author = "G Andersen and Christrup, {Lona Louring} and P Sj{\o}gren",
year = "1997",
month = may,
day = "26",
language = "Dansk",
volume = "159",
pages = "3383--6",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "22",

}

RIS

TY - JOUR

T1 - Morfinmetabolisme-farmakokinetik og-dynamik

AU - Andersen, G

AU - Christrup, Lona Louring

AU - Sjøgren, P

PY - 1997/5/26

Y1 - 1997/5/26

N2 - With the increasing use of morphine, growing interest for the clinical implications of its metabolites, morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G) has emerged in the literature. M-6-G binds to the opioid receptor and has analgesic properties in man. Clinical studies have not delivered strong evidence of significant correlation between the concentration of morphine and its glucuronides in plasma and cerebrospinal fluid and pharmacodynamics such as analgesia. There is no clinical evidence to indicate that M-6-G has a pronounced respiratory depressing effect in man, while the literature contains conflicting reports with regard to other side-effects. M-3-G does not bind to the m-opioid receptor and consequently has no antinociceptive effects. Studies in rodents have shown that morphine, M-6-G and especially M-3-G may induce hyperalgesia, allodynia and myoclonus. It is assumed that these side effects are caused by a spinal antiglycinergic mechanism. The role of M-3-G in morphine antagonism and development of tolerance has not yet been settled. As M-3-G and M-6-G are eliminated by the kidneys, renal insufficiency will lead to accumulation of these. Accordingly dosage should be reduced or other opioids be considered in such cases.

AB - With the increasing use of morphine, growing interest for the clinical implications of its metabolites, morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G) has emerged in the literature. M-6-G binds to the opioid receptor and has analgesic properties in man. Clinical studies have not delivered strong evidence of significant correlation between the concentration of morphine and its glucuronides in plasma and cerebrospinal fluid and pharmacodynamics such as analgesia. There is no clinical evidence to indicate that M-6-G has a pronounced respiratory depressing effect in man, while the literature contains conflicting reports with regard to other side-effects. M-3-G does not bind to the m-opioid receptor and consequently has no antinociceptive effects. Studies in rodents have shown that morphine, M-6-G and especially M-3-G may induce hyperalgesia, allodynia and myoclonus. It is assumed that these side effects are caused by a spinal antiglycinergic mechanism. The role of M-3-G in morphine antagonism and development of tolerance has not yet been settled. As M-3-G and M-6-G are eliminated by the kidneys, renal insufficiency will lead to accumulation of these. Accordingly dosage should be reduced or other opioids be considered in such cases.

KW - Humans

KW - Morphine

KW - Receptors, Opioid, mu

M3 - Tidsskriftartikel

C2 - 9199024

VL - 159

SP - 3383

EP - 3386

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 22

ER -

ID: 46098790